U.S. Stem Cell, Inc. (OTCQB: USRM) is a biotechnology company that focuses on stem cell therapies and treatments. The biotech company is gaining 18.18%, through early trading on Thursday, March 9, 2017. Over the past three months, U.S. Stem Cell, Inc. has seen average daily volume of 16.33 million shares. However, volume of 9.38 million shares or dollar volume of $216,678, has already exchanged hand on Thursday.

Shares of U.S. Stem Cell, Inc. are climbing Thursday, after the company announced that it has appointed Greg Knutson to the company’s board of directors. Knutson has 30 years of business and financial experience and is a key manager at NorthStar Biotech, LLC. The appointment comes as U.S. Stem Cell, Inc. and NorthStar Biotech, LLC settle legal disputes. Here is the full press release detailing of the new board appointment:

U.S. Stem Cell, Inc. Press Release:

SUNRISE, FL / ACCESSWIRE / March 7, 2017 / U.S. Stem Cell, Inc., (USRM) a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies for human and animal patients, is pleased to announce that Greg Knutson, the Manager of NorthStar Biotech, LLC, has joined the Board of Directors of U.S. Stem Cell, Inc.

“We are very pleased that Greg Knutson, a longtime supporter of the U.S. Stem Cell family of companies, has agreed to join our Board and assist us to continue with our recent technological advances and financial accomplishments,” said Mike Tomas, President and CEO of U.S. Stem Cell, Inc. A longtime U.S. Stem Cell shareholder and supporter, Knutson brings more than 30 years of business and financial experience to the organization. During his entrepreneurial career, Knutson founded Concrete Specialists, Inc. and continues to serve as its President; is the founder and current President of Sunwood Properties; and is the founder and Managing Partner of G&G Land Development, LLC.

Demonstrating a progressive step forward, Knutson joins the Board of Directors just as the two companies amicably settled a legal dispute related to NorthStar’s preferred shares.

About U.S. Stem Cell, Inc.

US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Our business, which includes three operating divisions (US Stem Cell Training, Vetbiologics and US Stem Cell Clinic) includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2015, and its Quarterly Reports on Form 10-Q.

Add a Comment to this Post